OJEMDA Trademark
OJEMDA is a USPTO trademark filed by Day One Biopharmaceuticals, Inc.. Status: Registered.
Trademark Facts
| Mark | OJEMDA |
|---|---|
| Serial Number | 98244532 |
| Registration Number | 7871548 |
| Status | Registered |
| Filing Date | 2023-10-27 |
| Registration Date | 2025-07-22 |
| Mark Type | Combined |
| Nice Classes | 005 (Pharmaceuticals), 042 (Software & IT), 044 (Medical Services) |
| Owner | Day One Biopharmaceuticals, Inc. |
| Attorney of Record | Connie L. Ellerbach |
| Prosecution Events | 28 |
| Latest Event | R.PR on 2025-07-22 |
Goods & Services
Pharmaceutical preparations for human use for the treatment of cancer; pharmaceutical preparation for the prevention and treatment of cancer; pharmaceutical preparations for the treatment of oncological diseases; pharmaceutical preparations and substances for the prevention and treatment of oncological diseases and disorders; targeted pharmaceutical preparations for use in the field of cancer prevention and treatment; pharmaceutical preparations for the delivery of compounds to the body for the treatment and prevention of oncological related diseases and disorders;; Medical information services; healthcare services, namely, providing cancer treatment information to physicians, health care professionals, and patients; medical information services, namely, providing information regarding oncological diseases and disorders; Research, development, and product evaluation of pharmaceutical preparations for the prevention and treatment of cancer; laboratory analysis and research of drugs and pharmaceutical products; research and development services in the fields of oncology, immunotherapy, chemotherapy, and combination therapies for the treatment of cancer and tumors; providing medical research information in the fields of oncology, immunotherapy, chemotherapy and combination therapies; scientific advisory services, namely, providing scientific information, advice, and consultancy in the field of cancer treatment; design, development, research, and testing of new products, namely, drugs and pharmaceuticals for the treatment and/or prevention of oncological diseases and disorders